McKinsey October 30, 2020
Brian Bradbury of Amgen’s Center for Observational Research discusses the power of data and analytics to advance the understanding of disease, therapeutic interventions, and clinical outcomes.
Non-interventional or observational research is playing an increasingly important role in our understanding of the clinical and economic costs of disease and the benefits and risks of therapeutic interventions. Brian Bradbury, vice president and head of the Center for Observational Research (CfOR), spoke with McKinsey’s Anna Draganova Beloff and Lucy Pérez about how the center is building capabilities to take advantage of shifts in the data environment to advance healthcare delivery and patient outcomes. An edited excerpt of their conversation follows.
McKinsey: What first prompted Amgen to invest in data and analytics?
Brian Bradbury:...
Today's Sponsors
Today's Sponsor